Forging the Way Ahead to Better Drug Development for NASH Patients, Upcoming Webinar Hosted by Xtalks

Share Article

The staggering public health implications of non-alcoholic steatohepatitis (NASH) have fueled research and investment toward diagnostics and treatments, but many hurdles remain in bringing effective therapies to patients. In this free webinar, a panel of speakers – from doctors, to patients, to drug developers - will explore these challenges and how we might overcome them.

Xtalks Life Science Webinars

The limitations of liver biopsy have driven a search for non-invasive NAFLD screening and risk stratification methods. Since advanced fibrosis has been proven to be prognostic of poor outcomes in NAFLD, multiple surrogate fibrosis markers have been studied, including imaging methods.

Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research in a live session on Tuesday, September 10, 2019 at 1pm EDT to learn about two common imaging methods in NAFLD/NASH to aid with early disease diagnosis, risk stratification and effective management.

NAFLD is the most common diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided into simple steatosis and NASH.

Patients with NAFLD are at risk of steatohepatitis and progressive liver fibrosis culminating in cirrhosis, typically over a period of decades.

Although liver biopsy is currently the gold standard for diagnosing progressive NASH, it has many drawbacks, such as sampling error, cost and risk of complications. Furthermore, it is not realistic to perform liver biopsies on all NAFLD patients.

The limitations of liver biopsy have driven a search for non-invasive NAFLD screening and risk stratification methods. Since advanced fibrosis has been proven to be prognostic of poor outcomes in NAFLD, multiple surrogate fibrosis markers have been studied, including imaging methods.

The two most prevalent imaging techniques to examine NAFLD and NASH patients are:

  •     Magnetic resonance elastography (MRE) — a technique that builds upon magnetic resonance imaging (MRI) to determine the stiffness of the liver, which can be used to determine the degree of fibrosis
  •     Proton density fat fraction (PDFF) — an MRI technique that can accurately determine the amount of fat in the liver (steatosis)

In this free webinar, the featured speaker will discuss these imaging methods, how they may be used for NAFLD/NASH screening, diagnosis & risk stratification, and other imaging techniques that may provide value in NAFLD/NASH patients.

For more information or to register for this event, visit Imaging for NAFLD/NASH: Current State and Future Trends.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
(416) 977-6555 x400
Email >
Visit website